Linda Burkly
Fortuna: 202 076 $ al 30/06/2026
Fortuna: 202 076 $ al 30/06/2026
Linda C.
Burkly is Chief Scientific Officer & Executive VP at Editas Medicine, Inc. since 2023.
Formerly, Dr. Burkly was Vice President & Senior Distinguished Investigator at Biogen, Inc. from 2014 to 2022.
Education includes an undergraduate degree from Fairfield University and a doctorate from Tufts University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
EDITAS MEDICINE, INC. 0,04 % | 28/07/2026 | 62.369 ( 0,04 % ) | 202 076 $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| EDITAS MEDICINE, INC. | Director Técnico/Científico/I+D | 24/07/2023 |
| Empresas | Cargo | Fin |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01/01/2022 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Biogen, Inc.
Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Fairfield University
Fairfield University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tufts University
Tufts University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Editas Medicine, Inc.
Editas Medicine, Inc. BiotechnologyHealth Technology Manufactures gene editing medicines | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.